Long-term follow-up of 84 patients with giant prolactinomas - a Swedish nationwide study.

DAs effectively reduced PRL and tumor size, but approximately one patient out of four needed multimodal treatment. Our results suggest that the response to DA after one year is useful for identifying patients who need more careful monitoring and, in some cases, additional treatment.